Key Words: type 2 diabetes mellitus, quality of life, self-efficacy, microvascular complications
Quality of life and self-efficacy assessments are increasingly applied in research with type 2 diabetes mellitus patients due to the impact of the disease on their lives. This study aimed to describe the quality of life and self-efficacy in type 2 diabetes mellitus patients and describe the association of quality of life and self-efficacy with demographic, metabolic, and clinical variables. This is a secondary data analysis from a cross-sectional study: “Metabolic control in patients with type 2 diabetes mellitus in a public hospital in Peru: a cross-sectional study in a low-middle income country”. Data were obtained by standardized interviews and evaluation of medical records. The evaluation tools used were the Diabetes 39 questionnaire (D-39) to measure the quality of life and the General Self-Efficacy scale (GSE) for self-efficacy. The median scores of the D-39 and GSE were 34.6 and 34, respectively. The D-39 dimension with the highest score was “anxiety and concern.” Better quality of life was associated with being older than 65 years old, not having complications, and the absence of depression. No significant association was found between self-efficacy and the quality of life score. Results suggest patients with type 2 diabetes mellitus have a poor quality of life. Patient-centered strategies for type 2 diabetes mellitus care must consider these psychosocial factors to improve disease control and quality of life.
Main messages
|
Type 2 diabetes mellitus is a chronic disease with a growing worldwide prevalence that greatly impacts patients’ quality of life[1]. According to the International Diabetes Federation (IDF), in 2019, 463 million adults were living with diabetes; it has been estimated that by 2045 this number will rise to 700 million people, with type 2 diabetes mellitus as its majority, with 90% of cases[2] and low- and middle-income countries the most affected[2],[3]. In Peru, the current prevalence is 7.1%[4], which represents the people at risk of type 2 diabetes-related complications, disabilities[2], and psychosocial impairments[1],[5] that will decrease their quality of life.
Quality of life studies in chronic diseases has gained interest in the diabetes epidemic due to the importance of health interventions in improving physical wellness and a more holistic approach in patient care of improving overall well-being[1],[2]. Moreover, it is used as a patient-important outcome in clinical trials[6]. The World Health Organization (WHO) defines quality of life as an individual’s perception of their position in life in the context of the culture and value systems they live, having to do with their goals, expectations, standards, and concerns[7]. For example, studies have found clinical and metabolic factors, such as the presence of two or more complications, inadequate glycemic control, and more invasive treatment; harm quality of life[8], affecting medical, social, economic, and psychological factors in each patient[9]. However, psychological factors, such as depression, could be more important in predicting quality of life since these have proved to be stronger predictors of hospitalization and mortality[5].
Patients with type 2 diabetes mellitus may develop distress due to a sense of loss of control in their lives, overwhelming self-care stress, feelings of loneliness, and the fear of disease complications and death[10],[11]. Self-management activities, such as glycemic control or adherence to a new diet, may be perceived as mentally and physically exhausting, highly influenced by internal (mood, energy, etc.) and external stressors (economics, family issues, etc.)[11], which are subsequently associated with glucose control impairment[12]. Diabetes management requires time and emotional work from patients and their families. It has been estimated that practicing the self-care activities recommended by the American Diabetes Association (ADA), e.g., checking feet, monitoring glucose, and exercising, requires more than two hours per day[13].
On the other hand, a positive attitude and resilience are associated with better clinical outcomes such as lower overall mortality and lower one-year glycosylated hemoglobin (HbA1c) levels in patients with diabetes[14]. Therefore, quality of life assessments should be included and considered essential in these patients’ medical management. The main goal in medical practice is to minimize the deterioration of quality of life[15].
Another crucial factor that affects every human endeavor is self-efficacy. It has a strong predictive association with morbidity and mortality in type 2 diabetes mellitus[16]. Self-efficacy is a psychological concept defined as the self-perception of one’s ability to perform and achieve goals[17]. High self-efficacy is associated with less reported pain, better self-care performance, more frequent healthy behaviors, and higher quality of life in patients with[18],[19] or without type 2 diabetes mellitus[20].
There are limited studies on the effect of psychosocial factors like quality of life and self-efficacy on type 2 diabetes mellitus patients in low- and middle-income countries, where external stressors such as poverty, healthcare access limitations, and family issues are frequent. This study aims to measure the quality of life and self-efficacy in type 2 diabetes mellitus patients at a public hospital in Lima, Peru, and examine the association between quality of life and self-efficacy with demographic, metabolic, clinical variables, and laboratory parameters.
Study design and participants
We conducted a secondary analysis of a cross-sectional study: “Metabolic control in patients with type 2 diabetes mellitus in a public hospital in Peru: a cross-sectional study in a low-middle income country”[21]. The study recruited participants with a type 2 diabetes mellitus diagnosis between March and July of 2012 in the Endocrinology Unit of the Cayetano Heredia Hospital in Lima, Peru.
Patients were recruited by convenience sampling. Inclusion criteria were as follows: diagnosis of type 2 diabetes mellitus for at least 12 months, being older than 18 years old, and more than one visit to the Endocrinology Unit in the previous year. Patients were excluded if they had secondary or gestational diabetes, chronic non-cardio-metabolic diseases (systemic lupus erythematosus, rheumatoid arthritis, chronic obstructive pulmonary disease), major complications of type 2 diabetes mellitus (stroke, coronary heart disease, hyperglycemic/hypoglycemic crisis) in the previous year, hospitalization in the last six months, or a diagnosed mental illness or incapability.
Procedures
Information was collected by a standardized interview and evaluation of medical records. Data for demographic variables, clinical factors related to treatment, and chronic diabetic complications defined as microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (coronary heart disease, stroke, and peripheral artery disease) were also obtained.
The evaluation forms and standardized tools used were: Diabetes 39 questionnaire (D-39)[22] and the General Self-Efficacy scale of Schwarzer and Baessler[23].
Laboratory measurements for fasting glucose, HbA1c, and lipid profile were taken in the morning after, at minimum, an 8-hour fast. Evaluation forms and standardized interviews were assessed during the endocrinology visit.
Outcomes and variables definition
The D-39 item questionnaire assesses five dimensions: energy and motility, diabetes control, anxiety and concern, social and peer burden, and sexual functioning. The D-39 also contains two final items that rate the patients’ perception of their overall quality of life and diabetes severity. The answers reflect the degree of affectation that diabetes had on the previous month for each of the five items named previously. The participant expressed answers on a visual analogic scale from 1 to 7, where 1 means “not affected at all” and 7 means “extremely affected.” In the case of overall quality of life and diabetes severity, 1 means “lowest quality of life,” and 7 means “highest quality of life,” or 1 means “less severe” and 7 “extremely severe,” respectively. Once finished, each section’s partial scores are transformed into a scale from 0 to 100, and the median determines the cutoff points. The patient is considered to have a better quality of life if the individual total score is lower than the median and poor quality of life if the score is equal or greater than the median[22].
Schwarzer and Baessler’s GSE evaluation consists of ten items with four possible answers: “not true at all,” “hardly true,” “moderately true,” and “exactly true.” The “not true at all” alternative is given a value of 1, whereas “exactly true” received a value of 4. The participant gets a total score on a range from 10 to 40. A higher score represents a higher self-efficacy[23]. There is no cutoff point to define if a subject is considered self-efficacious, but the subject’s score is compared to the mean scores of those in other groups.
“Good metabolic control” was defined according to ADA recommendations: good glycemic control (HbA1c < 7%), controlled blood pressure (BP < 140/90mmHg), and controlled LDL-cholesterol (LDL < 100 mg/dL)[24].
A detailed explanation of variables and scales can be seen in Table 1.
Table 1. Variables and score definition
Statistical analysis
Statistical analysis was performed using Stata 13.0. Chi-square test was used for estimating the association between demographic (age, gender, marital status), metabolic (BMI, HbA1c, LDL, BP), and clinical (disease duration, treatment, complications) variables compared to the quality of life (D-39). The non-parametric Mann-Whitney test was used to examine the association between demographic and clinical variables with GSE score. A Spearman correlation test was performed to examine the association between each quality of life dimension and the GSE score.
Multivariable models were generated using Poisson regression reporting prevalence ratios and 95% confidence interval. This model evaluated the independent association among quality of life and demographic, metabolic, and clinical variables. Crude and adjusted analyses were performed.
Ethics
The Institutional Review Boards of the Universidad Peruana Cayetano Heredia and Hospital Cayetano Heredia both approved the study protocol. Written consent was obtained from all participants.
The sample was composed of 42 men (34.2%) and 81 women (65.9%). The mean age was 61.8 ± 11.1 years old. Further characteristics are described in Supplementary material 1.
Quality of life dimensions and self-efficacy
The overall median for the total score of D-39 was 34.6 (IQR 19.7 to 51.3). The D-39 dimension with the highest score, almost doubling the total score median, was “anxiety and concern” with a median of 66.7 (IQR: 33.3 to 83.3); the dimension with the lowest score was “sexual functioning” with a median of 0 (IQR: 0.0 to 50.0). On the general self-efficacy score, the sample median was 34. In table 2, we reported in detail the scores of every item for D-39 and GSE.
Table 2. Quality of life dimensions and self-efficacy
Quality of life and self-efficacy associated with co-variables
In the bivariate analysis, we found a significant association between better quality of life and being older than 65 years old (p = 0.01), not having microvascular diabetes complications (p = 0.02), and not having depression (p < 0.001). There were no significant associations between self-efficacy and demographic, clinical, or metabolic variables; all p-values > 0.05 (Table 3).
Table 3. Characteristics of the study population according to quality of life and self-efficacy
Multivariate analysis of quality of life
In the crude analysis, the proportion of poor quality of life was 46% higher in people with either microvascular or macrovascular complications (PR = 1.46, 95% CI 1.03 to 2.07, p = 0.03). In the adjusted multivariate analysis, poor quality of life was two times higher compared to those living without depression (PR = 2.34, 95% CI 1.62 to 3.31); 45% higher in people living more than ten years with diabetes (PR = 1.45, 95% CI 1.01 to 2.13); two times higher in people treated only with insulin compared to no pharmacological treatment (PR = 2.02, 95% CI = 1.01 to 4.07); and 34% lower in people older than 65 years (PR = 0.66, 95% CI 0.43 to 1.00) (Table 4).
Table 4. Factors associated with quality of life
Association between quality of life dimensions and self-efficacy
We did not find an association between the general self-efficacy score and the overall quality of life score (p = 0.690), but there were significant associations between some quality of life dimensions. For example, there was a negative correlation between self-efficacy and “anxiety and concern” (rho = -0.20, p < 0.05), as well as with diabetes severity (rho = -0.22, p < 0.05), and a positive correlation with the overall perception of the quality of life (rho = +0.25, p < 0.01) (Table 5). Graphics are shown in Supplementary material 2.
Table 5. Quality of life and self-efficacy correlation
Patients with type 2 diabetes mellitus presented low quality scores (median of 34.62 for D-39), “anxiety and concern” and “energy and motility” being the most frequently reported dimensions. Even though there are different patterns within Latin American publications, “anxiety and concern” is one of the most commonly reported[22],[25],[26]. Also, we found that quality of life was associated with depression, which has been reported as an associated factor to poor metabolic outcomes[27],[28],[29]. These findings suggest that diabetes hurts the psychological domain of quality of life, which must be addressed to avoid mental health disorders like depression associated with poor metabolic outcomes[30].
We also found higher quality of life scores among patients older than 65, suggesting that greater distress is experienced by young adults with type 2 diabetes mellitus than among the elderl[31],[32],[33].
Our model found that the association between diabetic complications and quality of life was no longer significant when controlling by years of disease and insulin therapy variables. This confounder effect is explained by previous studies that report the association between years of diabetes and insulin therapy with the appearance of complications[34] and worse quality of life scores[35],[36].
We did not find significant associations between quality of life and marital status, metabolic control, years of disease, or any treatment. Some studies found that quality of life was positively associated with being in a couple. Furthermore, they emphasized that family members or other social support should be addressed as a predictor for quality of life[36]. The associations between metabolic control or comorbidities with quality of life have been inconsistent in the literature, but it is known that a poor metabolic control leads to complications that may affect the quality of life. Nonetheless, there is no consensus over its direct effect[1],[26],[35],[37].
We found a median for general self-efficacy of 31.7, which means that type 2 diabetes mellitus patients are less likely to feel empowered to achieve goals related to their disease. Similar values have been reported in an ethnically diverse study with patients with diabetes performed in the United States[38]. There was no association found between self-efficacy and other variables, unlike other scales designed to measure self-efficacy in a patient with diabetes such as IMDSES (Insulin Management Diabetes Self-Efficacy Scale), DSE (Diabetes Self-Efficacy), and DDS2 (Diabetic Distress Score) that reported associations between self-efficacy and demographic and clinical variables. Diabetic-specific self-efficacy scales may be more sensitive about finding differences with other variables among patients with diabetes[39],[40],[41],[42].
The general self-efficacy score was not significantly associated with the quality of life score. However, we have seen that an increase in the self-efficacy points was associated with a parallel increase in the points of “quality of life perception” and fewer points over “diabetes severity” and “anxiety and concern.” The findings are similar to those reported by Kim G, et al., where self-efficacy is correlated with less psychological distress, which is important for adjusting healthier lifestyles necessary for diabetes control[40].
One of the study limitations, as a cross-sectional study, is the causality in the association between quality of life and self-efficacy with other variables that could not be determined. Also, our sample was limited to the Endocrinology clinic of a public hospital, which lowers the findings’ external validity. Potentially important variables were not included, such as language, comorbidities, family support, number of family members living with the patient, education, knowledge of diabetes, or number of hospitalizations. These variables have been reported to be relevant to the quality of life and self-efficacy and may act as a confounder in some studies.
Our findings revealed the complexity of managing various social and psychological stressors that can affect the quality of metabolic control and quality of life in the medium- or long-term. Clinicians tend to focus on symptoms, signs, medications, and evaluation of laboratory parameters to determine the next steps for managing people with type 2 diabetes mellitus. Few clinicians apply for patient-centered medicine, an approach defined as “taking into account patients’ preferences, objectives, and values, as well as the available economic resources”[43]. In this context, an approach like “Minimally disruptive medicine,” a patient-centered approach that seeks reduction of a patient’s life disruption due to medical treatment by taking into account the patient’s health and general life goals, could influence in reducing “anxiety and concern” that harm a patient’s quality of life[44]. Our goal with this study is to fill the gap in understanding diabetes’s impact on patients’ quality of life. This study, performed in a public hospital that receives patients of diverse socioeconomic status, shows the reality our patients are facing with the burden of the disease and what should be considered for diabetes care.
The quality of life in patients with type 2 diabetes mellitus is poor, “anxiety and concern” being the most affected dimension. Poor quality of life was associated with being younger than 65 and with having depression. There was no association found between self-efficacy and quality of life. Our findings emphasized the impact that diabetes has on the patient’s psychology and life. A patient-centered approach is needed to improve quality of life, which is as important as glycemic control and complication prevention from the patient’s perspective.
Notes
Authorship contributions
All authors contributed equally to this study.
Competing interests
The authors declare there is no competing interests to declare regarding this work.
Funding
The main study was supported by a research fund from the Faculty of Medicine Alberto Hurtado, Universidad Peruana Cayetano Heredia (No. 02231001). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Acknowledgments
The authors thank Dr. Ray Ticse, Dr. Miguel Pinto, and Dr. Valerie Paz Soldan for their valuable comments and review on this article and Mariela Florez and Carmela Costta for their help in patient recruitment.
Data availability statement
The raw data of the main study is available in 10.7717/peerj.2577/supp-2.
La calidad de vida y la evaluación de autoefiacia se aplican cada vez más en la valoración de los pacientes con diabetes mellitus tipo 2 debido al alto impacto de la enfermedad en sus vidas. Este estudio tiene como objetivo describir la calidad de vida y autoeficacia en pacientes con diabetes mellitus tipo 2 y describir la asociación de calidad de vida y autoeficacia con variables demográficas, metabólicas y clínicas. Este estudio es un análisis secundario del estudio transversal: “Control metabólico en pacientes con diabetes mellitus tipo 2 en un hospital público del Perú: estudio de corte transversal en un país de bajos y medianos ingresos”. Los datos se obtuvieron mediante cuestionarios estandarizadas y evaluación de historias clínicas. Las herramientas de evaluación utilizadas fueron el cuestionario Diabetes -39 (D-39) para medir la calidad de vida y la escala de autoeficacia general para medir autoeficacia (GSE). Las medias del D-39 y GSE fueron 34,6 y 34, respectivamente. La dimensión con la puntuación más alta del D-39 fue "ansiedad y preocupación". Una mejor calidad de vida estuvo asociada con ser mayor de 65 años, no tener complicaciones microvasculares y la ausencia de depresión. No se encontró una asociación significativa entre la autoeficacia y calidad de vida. Los resultados sugieren que los pacientes con diabetes mellitus tipo 2 tienen una pobre calidad de vida. Las estrategias centradas en el cuidado del paciente con diabetes mellitus tipo 2 deben considerar estos factores psicosociales para mejorar el control de la enfermedad y la calidad de vida.
Citation: Huayanay-Espinoza IE, Guerra-Castañon F, Reyes-Diaz M, Lazo-Porras M, de la Cruz-Luque C, Herrera DA, et al. Quality of life and self-efficacy in patients with type 2 diabetes mellitus in a Peruvian public hospital. Medwave 2021;21(02):e8132 doi: 10.5867/medwave.2021.02.8132
Submission date: 30/3/2020
Acceptance date: 12/12/2020
Publication date: 22/3/2021
Origin: Not commissioned.
Type of review: Externally peer-reviewed by four reviewers, double-blind.
We are pleased to have your comment on one of our articles. Your comment will be published as soon as it is posted. However, Medwave reserves the right to remove it later if the editors consider your comment to be: offensive in some sense, irrelevant, trivial, contains grammatical mistakes, contains political harangues, appears to be advertising, contains data from a particular person or suggests the need for changes in practice in terms of diagnostic, preventive or therapeutic interventions, if that evidence has not previously been published in a peer-reviewed journal.
No comments on this article.
To comment please log in